Immuno-oncology Tolerance induction / PHAXIAM Therap, STEMCELL Technologies - LARVOL DELTA

STEMCELL Technologies Announces Successful Completion of Asset Purchase Agreement with SQZ Biotechnologies Company [Google translation] (Businesswire) - "STEMCELL Technologies is pleased to announce that it has acquired substantially all of the assets of SQZ Biotechnologies Company...This transaction, which was approved today by SQZ shareholders, marks another important milestone for STEMCELL, Canada's largest biotechnology company....Once the SQZ transaction was approved, STEMCELL was able to acquire substantially all of SQZ's assets, including its entire portfolio of more than 400 patents and trademarks, other intellectual property rights such as copyrights and trade secrets, proprietary equipment and its master license from the Massachusetts Institute of Technology."

M&A • Cervical Cancer • CNS Disorders • Gynecologic Cancers • Head and Neck Cancer • Oncology • Parkinson's Disease • Solid Tumor